Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink
- PMID: 21810637
- DOI: 10.1001/archpediatrics.2011.112
Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink
Abstract
Objectives: To evaluate the safety of trivalent inactivated influenza vaccine (TIV) in children aged 24 to 59 months and to evaluate the risk of medically attended events (MAEs) in a subcohort of children who had multiple annual doses of TIV over their lifetimes.
Design: Self-controlled screening study.
Setting: Seven US managed care organizations from October 1, 2002, to March 31, 2006.
Participants: Children aged 24 to 59 months who received at least 1 TIV dose (66 283 children and 91 692 TIV doses).
Exposure: Vaccination with TIV.
Main outcome measures: Medically attended events in inpatient and emergency department settings in one of the following risk windows: 0 to 2, 1 to 14, or 1 to 42 days after vaccination. All MAEs that met the screening criteria of incidence rate ratios (IRRs) exceeding 1.0 and P ≤ .05 or IRRs exceeding 2.0 and P < .20 underwent medical record review. A secondary analysis examined the risk of MAEs in children who had multiple annual lifetime TIV doses.
Results: Nine diagnoses met the screening criteria. After medical record review, gastrointestinal tract symptoms (IRR, 1.18; 95% confidence interval [CI], 1.10-1.25), gastrointestinal tract disorders (7.70; 1.11-53.52), and fever (1.71; 1.64-1.80) remained significantly associated with vaccination. None of the events seemed to be serious, and none had complications. In the secondary analysis, there was an apparent dose response for vaccine and allergic reactions in the 1- to 3-day risk window.
Conclusions: There was no evidence of serious MAEs following vaccination with TIV among children aged 24 to 59 months. Further studies are warranted to evaluate the risk of MAEs in children with multiple lifetime TIV doses.
Similar articles
-
Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.Vaccine. 2012 Mar 2;30(11):2024-31. doi: 10.1016/j.vaccine.2012.01.027. Vaccine. 2012. PMID: 22361304
-
Safety of the trivalent inactivated influenza vaccine among children: a population-based study.Arch Pediatr Adolesc Med. 2004 Nov;158(11):1031-6. doi: 10.1001/archpedi.158.11.1031. Arch Pediatr Adolesc Med. 2004. PMID: 15520339
-
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.Vaccine. 2012 May 14;30(23):3389-94. doi: 10.1016/j.vaccine.2012.03.046. Epub 2012 Mar 30. Vaccine. 2012. PMID: 22469860 Clinical Trial.
-
The use of inactivated influenza vaccine in children.Semin Pediatr Infect Dis. 2006 Oct;17(4):200-5. doi: 10.1053/j.spid.2006.08.004. Semin Pediatr Infect Dis. 2006. PMID: 17055371 Review.
-
Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination.Pediatr Infect Dis J. 2004 Mar;23(3):189-97. doi: 10.1097/01.inf.0000116292.46143.d6. Pediatr Infect Dis J. 2004. PMID: 15014289 Review.
Cited by 12 articles
-
Statement on Seasonal Influenza Vaccine for 2012-2013: Appendix I: New Evidence Review for Children 24 to 59 Months of Age: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).Can Commun Dis Rep. 2012 Aug 1;38(ACS-2):1-55. doi: 10.14745/ccdr.v38i00a02a. eCollection 2012 Aug 1. Can Commun Dis Rep. 2012. PMID: 31702744 Free PMC article. No abstract available.
-
Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review.BMJ Glob Health. 2019 Jul 8;4(4):e001065. doi: 10.1136/bmjgh-2018-001065. eCollection 2019. BMJ Glob Health. 2019. PMID: 31354969 Free PMC article.
-
Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan.Rev Inst Med Trop Sao Paulo. 2018 Jul 30;60:e37. doi: 10.1590/S1678-9946201860037. Rev Inst Med Trop Sao Paulo. 2018. PMID: 30066805 Free PMC article.
-
Gastrointestinal Events in High-Dose vs Standard-Dose Influenza Vaccine Recipients.Open Forum Infect Dis. 2018 May 22;5(6):ofy115. doi: 10.1093/ofid/ofy115. eCollection 2018 Jun 1. Open Forum Infect Dis. 2018. PMID: 29942820 Free PMC article.
-
Vaccine-associated hypersensitivity.J Allergy Clin Immunol. 2018 Feb;141(2):463-472. doi: 10.1016/j.jaci.2017.12.971. J Allergy Clin Immunol. 2018. PMID: 29413255 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous